Nova Steroid Pharma Co.,Ltd
Top-Quality RU58841 Powder Treatment Of Androgen-Dependent Diseases CAS:154992-24-2

Top-Quality RU58841 Powder Treatment Of Androgen-Dependent Diseases CAS:154992-24-2

RU58841 (CAS 154992-24-2) represents a distinctive class of non-steroidal antiandrogens within the arylhydantoin family, initially developed by Roussel Uclaf during the 1990s as a topical therapeutic candidate for androgen-dependent dermatological conditions. Though the compound progressed to Phase 2 clinical trials for acne and androgenetic alopecia before being discontinued, it has persisted as a valuable research tool for investigators exploring topical androgen receptor antagonism without systemic hormonal disruption.

Send Inquiry
Description

   The Androgen Receptor Antagonist Paradigm

    RU58841 (CAS 154992-24-2) represents a distinctive class of non-steroidal antiandrogens within the arylhydantoin family, initially developed by Roussel Uclaf during the 1990s as a topical therapeutic candidate for androgen-dependent dermatological conditions. Though the compound progressed to Phase 2 clinical trials for acne and androgenetic alopecia before being discontinued, it has persisted as a valuable research tool for investigators exploring topical androgen receptor antagonism without systemic hormonal disruption. This examination provides a detailed exploration of RU58841 powder from the perspective of laboratory research, addressing its mechanism of action, physicochemical properties, research applications, and the pharmacological parameters relevant to experimental design.

v2-c511b5fe2a9b61b7260c74f2616793df1440w

Chemical Identity and Physical Properties

    RU58841 possesses the molecular formula C₁₇H₁₈F₃N₃O₃ with a molecular weight of 369.34 g/mol. The compound is supplied as a white to off-white solid powder, typically with purity exceeding 98% as verified by high-performance liquid chromatography. Its chemical structure incorporates a trifluoromethyl group and a nitrile moiety, features that contribute to its high-affinity binding to the androgen receptor.

    The solubility profile of RU58841 is a critical consideration for researchers formulating topical vehicles. The compound demonstrates excellent solubility in dimethyl sulfoxide, with reported concentrations reaching 64 mg/mL (approximately 173 mM). It also exhibits solubility in dimethylformamide and ethanol at concentrations up to 33 mg/mL. This solubility versatility allows investigators to prepare stock solutions and working dilutions across a range of experimental concentrations. For optimal dissolution, researchers may warm the solution to 37°C with ultrasonic agitation.

    Storage requirements for RU58841 powder are well-characterized. The desiccated powder remains stable for over two years when stored at -20°C, while solution-phase storage at -20°C is recommended for periods up to one month. Short-term storage at 4°C is acceptable for days to weeks. These parameters ensure experimental reproducibility when appropriate handling protocols are followed.

Mechanism of Action: Molecular Antagonism at the Androgen Receptor

    The fundamental mechanism by which RU58841 exerts its effects involves competitive antagonism at the androgen receptor (AR). The compound binds to the AR with high affinity, displaying dissociation constants (Kd) of 1.8 nM for the human androgen receptor, 1.1 nM for the rat receptor, 5.6 nM for the mouse receptor, and 1.3 nM and 1.4 nM for hamster prostate and flank organ receptors, respectively. This binding affinity positions RU58841 as a potent competitor for endogenous androgens, particularly dihydrotestosterone (DHT) and testosterone.

    The molecular mechanism of AR antagonism by RU58841 has been elucidated through transfection studies using human prostate cancer PC3 cells. When wild-type androgen receptor was co-transfected with an androgen-responsive reporter construct, neither RU58841 nor other antiandrogens (hydroxyflutamide, Casodex) enhanced AR transcriptional activity across concentrations ranging from 10⁻¹¹ to 10⁻⁷ M. However, these compounds demonstrated competitively suppressive effects on DHT-induced AR activation. The potency of RU58841 in this regard was comparable to that of hydroxyflutamide, establishing it as a genuine antagonist rather than a partial agonist.

    Crucially, RU58841 does not activate the androgen receptor in the absence of androgens. This distinguishes it from certain other antiandrogens that may exhibit agonistic properties under specific conditions. The compound's antagonism is competitive in nature-it occupies the ligand-binding domain of the AR, preventing DHT from binding and subsequently blocking the downstream transcriptional events that would otherwise lead to androgen-mediated gene expression.

Tissue Selectivity and Localized Activity

    The defining characteristic of RU58841 that renders it particularly valuable for dermatological research is its pronounced tissue selectivity. When administered topically, the compound exerts potent local effects while demonstrating minimal systemic antiandrogenic activity. This property was demonstrated in hamster models where topical application of RU58841 induced dose-dependent regression of flank organ area at doses as low as 1 μg per animal, yet remained devoid of antiandrogenic effects on deep accessory sex organs and did not alter testosterone levels even at doses up to 100 μg per animal.

    The tissue selectivity appears to derive from several factors. First, topical administration delivers the compound directly to target tissues-the hair follicle and sebaceous gland-where androgen receptors mediate the pathological effects of DHT. Second, the compound's pharmacokinetic profile, characterized by a short plasma half-life of less than one hour, limits systemic exposure. Third, RU58841 undergoes minimal conversion to active metabolites; approximately only 1% converts to the active metabolite RU56279, compared to 77% for the analog RU56187. This metabolic profile further confines activity to the site of application.

    In primate studies using the stumptailed macaque model of androgenetic alopecia, topical RU58841 application produced a potent increase in hair density, thickening, and length, while no systemic effects were detected. The compound has also demonstrated efficacy in human scalp xenograft models, where a 1% topical formulation yielded a 103% increase in healthy hair follicle counts, surpassing the 88% increase observed with oral finasteride.

Research Applications and Experimental Models

    RU58841 powder serves as a research tool across multiple experimental domains. The primary application involves investigating the role of androgen receptor signaling in hair follicle biology and sebaceous gland function. Researchers utilize the compound to study androgen-dependent skin disorders including androgenetic alopecia, acne, and hirsutism.

    In vitro applications include cell culture studies examining AR-mediated transcription, where RU58841 is used to block androgen-induced gene expression in relevant cell lines such as dermal papilla cells and sebocytes. The compound's high receptor binding affinity and specificity make it suitable for receptor binding assays and competition studies.

    In vivo research models have included the hamster flank organ model for evaluating sebaceous gland suppression, the stumptailed macaque model for androgenetic alopecia, and human scalp xenograft models on testosterone-conditioned nude mice. These models have consistently demonstrated RU58841's ability to promote hair growth and reduce androgen-mediated tissue responses.

    Recommended usage concentrations in research formulations range from 0.1% to 5%. For topical applications, the compound is typically dissolved in vehicles such as ethanol, propylene glycol, or combinations thereof. Researchers should note that RU58841 is classified as a research chemical and is not approved for human therapeutic use.

Pharmacokinetic Parameters and Half-Life Considerations

    The pharmacokinetic profile of RU58841 is characterized by a notably short plasma half-life of less than one hour. This parameter has significant implications for experimental design and interpretation. The short systemic half-life means that any compound that does enter circulation is rapidly cleared, limiting potential systemic effects.

    However, the relationship between plasma half-life and duration of action at the receptor level requires careful interpretation. The short plasma half-life does not necessarily indicate a brief duration of receptor occupancy. The compound's binding to the androgen receptor may persist considerably longer than its presence in circulation. Anecdotal evidence suggests the effective period of androgen receptor inhibition may extend to approximately 48 hours.

    Topical application provides additional pharmacokinetic advantages. The route avoids extensive first-pass hepatic metabolism, particularly N-dealkylation pathways that would otherwise inactivate the compound. This allows effective regional treatment concentrations to be achieved with lower total compound exposure compared to systemic administration.

Dosing Considerations and Experimental Cycles

    In research settings, RU58841 dosing varies considerably depending on the experimental model and endpoint. In the hamster flank organ model, topical doses as low as 1 μg per animal produced measurable effects. In primate studies, a 5% (v/v) formulation was applied to bald frontal scalps. For human scalp xenograft models, 1% topical formulations in ethanol have been employed.

    The concept of "cycling" RU58841 in research contexts differs substantially from the cycling protocols associated with anabolic-androgenic steroid use. For RU58841, cycling refers to the pattern of topical application rather than a post-cycle therapy requirement. Typical research protocols involve daily application, with some investigators exploring every-other-day regimens based on the compound's prolonged receptor occupancy.

    Discontinuation of RU58841 application results in the gradual return of androgen receptor availability, as the compound does not permanently alter receptor expression or function. The androgen receptors remain present; they are simply occupied by the antagonist during active treatment. Upon cessation, endogenous androgens can again bind and initiate signaling.

Post-Cycle Considerations: A Nuanced Perspective

    The question of post-cycle therapy following RU58841 use in research contexts requires careful distinction from the PCT protocols associated with anabolic steroid cycles. RU58841 functions as a receptor-level antagonist rather than a suppressor of endogenous androgen production. It does not affect testosterone synthesis, luteinizing hormone, or follicle-stimulating hormone. Therefore, the hypothalamic-pituitary-gonadal axis remains intact during RU58841 treatment.

    Unlike steroidal androgens that suppress endogenous testosterone production through negative feedback, RU58841's mechanism operates entirely at the target tissue level. The compound does not alter circulating androgen concentrations. Consequently, there is no physiological requirement for PCT to restore endogenous hormone production upon discontinuation.

    However, the concept of a "transition period" may be relevant when discontinuing RU58841 in research protocols. As receptor occupancy declines and endogenous androgens regain access to the AR, the biological effects mediated by androgen signaling will gradually return. Researchers should consider this gradual return when designing experiments and interpreting outcomes.

Safety and Handling Considerations

    As a research chemical, RU58841 requires appropriate laboratory handling procedures. The compound should be used only in controlled research environments with suitable personal protective equipment. The discontinuation of clinical development means that comprehensive human safety data remain limited, reinforcing the importance of responsible laboratory practices.

    Systemic exposure, while minimized through topical application, remains a consideration in research settings. The compound's ability to penetrate the skin means that some absorption occurs. Researchers should employ appropriate containment measures when handling the powder and preparing solutions.

Comparative Perspective: RU58841 Versus Systemic Antiandrogens

    RU58841 occupies a distinct position among antiandrogen research tools. Unlike finasteride, which inhibits the 5α-reductase enzyme responsible for converting testosterone to DHT, RU58841 acts directly at the receptor level. This mechanistic difference means RU58841 blocks the effects of both testosterone and DHT, whereas finasteride only reduces DHT formation while leaving testosterone unaffected.

    Compared to systemic antiandrogens such as flutamide or bicalutamide, RU58841 offers the advantage of topical delivery and tissue selectivity. Systemic antiandrogens affect androgen signaling throughout the body, while RU58841's effects can be localized to the site of application. This distinction makes RU58841 particularly valuable for studying androgen effects in skin and hair follicles without confounding systemic variables.

Clinical Data
Trade names RU58841;PSK-3841;HMR-3841
CAS 154992-24-2
Molar mass 369.344
MF C17H18F3N3O3
Purity Above 98%
Apprarance White Crystalline Powder

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

QQ20240306150406            product-948-1135                        product-521-245

 

Conclusion

    RU58841 powder represents a well-characterized research tool for investigating androgen receptor antagonism in dermatological contexts. Its high receptor binding affinity, tissue selectivity, and favorable topical pharmacokinetics make it suitable for studying androgen-dependent processes in hair follicles and sebaceous glands. The compound's short plasma half-life and minimal systemic effects allow researchers to interrogate localized androgen signaling without the confounds associated with systemic antiandrogen administration.

    For investigators designing experiments with RU58841, understanding its physicochemical properties, mechanism of action, and pharmacokinetic parameters is essential for developing robust research protocols. The compound's status as a discontinued clinical candidate does not diminish its value as a research tool; rather, it positions RU58841 as a well-studied antagonist with a defined pharmacological profile that continues to inform our understanding of androgen receptor biology in skin and hair.

Hot Tags: top-quality ru58841 powder treatment of androgen-dependent diseases cas:154992-24-2, China top-quality ru58841 powder treatment of androgen-dependent diseases cas:154992-24-2 manufacturers, suppliers, factory, Bodybuilding body function Methyltestosterone, Clostebol Acetate, High purity API Methenolone Enanthate, Nolvadex to treat or prevent breast cancer, Testosterone Phenylpropionate, Toremifene Citrate

Inquiry
goTop

(0/10)

clearall